Table 3.
Association between androgen deprivation therapy and type of cardiovascular events in patients diagnosed 2009 to 2015.
| Case | Person–years | Unadjusted HR (95% CI) | Adjusteda HR (95% CI) | |
|---|---|---|---|---|
| Angina | ||||
| Untreated | 260 | 24089 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 510 | 40923 | 1.1 (0.97,1.3) | 1.0 (0.88,1.2) |
| GnRH | 440 | 36370 | 1.1 (0.93,1.3) | 1.0 (0.86,1.2) |
| Degaralex | 16 | 818 | 1.7 (1.0,2.8) | 1.1 (0.64,1.8) |
| Bicalutamide | 30 | 1853 | 1.5 (1.0,2.2) | 1.1 (0.77,1.7) |
| Other antiandrogen | 24 | 1816 | 1.2 (0.79,1.8) | 1.1 (0.75,1.7) |
| Myocardial infarction | ||||
| Untreated | 201 | 24308 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 440 | 41352 | 1.4 (1.2,1.6) | 1.2 (1.0,1.5) |
| GnRH | 386 | 36759 | 1.4 (1.1,1.6) | 1.2 (1.0,1.5) |
| Degaralex | 12 | 819 | 1.8 (1.0,3.3) | 1.3 (0.70,2.3) |
| Bicalutamide | 26 | 1869 | 1.8 (1.2,2.7) | 1.5 (0.97,2.2) |
| Other antiandrogen | 16 | 1841 | 1.1 (0.67,1.9) | 0.95 (0.57,1.6) |
| Arrhythmia | ||||
| Untreated | 184 | 24221 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 414 | 41064 | 1.3 (1.1,1.6) | 1.2 (1.0,1.5) |
| GnRH | 357 | 36501 | 1.3 (1.1,1.5) | 1.2 (0.99,1.4) |
| Degaralex | 14 | 809 | 2.3 (1.32,3.9) | 1.6 (0.89,2.7) |
| Bicalutamide | 17 | 1879 | 1.2 (0.72,2.0) | 1.0 (0.61,1.7) |
| Other antiandrogen | 25 | 1811 | 1.8 (1.2,2.8) | 1.6 (1.1,2.5) |
| Heart failure | ||||
| Untreated | 104 | 24454 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 229 | 41639 | 1.4 (1.1,1.8) | 1.2 (0.95,1.6) |
| GnRH | 197 | 37018 | 1.4 (1.1,1.8) | 1.2 (0.94,1.6) |
| Degaralex | 8 | 821 | 2.2 (1.1,4.6) | 1.2 (0.58,2.6) |
| Bicalutamide | 16 | 1881 | 2.2 (1.3,3.7) | 1.9 (1.1,3.2) |
| Other antiandrogen | 8 | 1854 | 1.1 (0.54,2.3) | 0.80 (0.39,1.7) |
| Stroke | ||||
| Untreated | 226 | 24198 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 437 | 41206 | 1.2 (0.98,1.4) | 1.0 (0.88,1.2) |
| GnRH | 394 | 36621 | 1.2 (0.99,1.4) | 1.1 (0.90,1.3) |
| Degaralex | 6 | 818 | 0.80 (0.35,1.8) | 0.58 (0.25,1.3) |
| Bicalutamide | 12 | 1883 | 0.69 (0.39,1.2) | 0.62 (0.35,1.1) |
| Other antiandrogen | 24 | 1822 | 1.4 (0.94,2.2) | 1.2 (0.77,1.8) |
| Venous thromboembolism | ||||
| Untreated | 89 | 24459 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 273 | 41460 | 2.3 (1.8,3.0) | 2.3 (1.8,3.0) |
| GnRH | 243 | 36837 | 2.4 (1.8,3.1) | 2.3 (1.8,3.0) |
| Degaralex | 10 | 814 | 3.9 (2.0,7.5) | 3.7 (1.9,7.3) |
| Bicalutamide | 5 | 1902 | 0.92 (0.37,2.3) | 0.86 (0.35,2.1) |
| Other antiandrogen | 15 | 1842 | 2.8 (1.6,4.8) | 2.6 (1.5,4.6) |
| Other CVD events | ||||
| Untreated | 320 | 23967 | 1.00 (ref. cat.) | 1.00 (ref. cat.) |
| ADT | 726 | 40390 | 1.4 (1.2,1.6) | 1.3 (1.1,1.5) |
| GnRH | 657 | 35853 | 1.4 (1.2,1.6) | 1.3 (1.1,1.5) |
| Degaralex | 22 | 804 | 2.1 (1.3,3.2) | 1.7 (1.1,2.7) |
| Bicalutamide | 19 | 1843 | 0.79 (0.50,1.3) | 0.70 (0.44,1.1) |
| Other antiandrogen | 28 | 1826 | 1.2 (0.80,1.7) | 1.0 (0.69,1.5) |
ADT, androgen deprivation therapy; GnRH, gonadotropin-releasing hormone agonist;
Model contains for year of diagnosis, age, deprivation, comorbidities in the year before prostate cancer diagnosis (myocardial infarction, angina, cerebral vascular accident, heart failure, venous thromboembolism, arrhythmia, other cardiovascular disease, dementia, pulmonary disease, connective tissue disorder, peptic ulcer, liver disease, diabetes, diabetes complications, paraplegia, severe liver disease) and other medication use in the year before prostate cancer diagnosis (including separately aspirin, beta-blockers, ACEIs, ARBs, diuretics, statins, warfarin, digoxin, clopidogrel, dipyridamole, nitrate, insulin, sulfonylureas, metformin and other diabetic medications).